Rosty Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $9.11, for a total transaction of $22,146.41. Following the transaction, the chief executive officer now owns 187,471 shares in the company, valued at approximately $1,707,860.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total value of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total value of $437,495.52.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock remained flat at $9.09 on Thursday. The stock had a trading volume of 94,401 shares, compared to its average volume of 113,755. Fennec Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $11.92. The stock’s 50-day simple moving average is $10.07 and its 200 day simple moving average is $9.49.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The company had revenue of $9.74 million during the quarter, compared to analyst estimates of $9.47 million. As a group, research analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. HC Wainwright boosted their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Craig Hallum boosted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its holdings in Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock worth $34,000 after purchasing an additional 1,578 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Fennec Pharmaceuticals during the 3rd quarter worth approximately $50,000. Jump Financial LLC purchased a new position in shares of Fennec Pharmaceuticals in the 4th quarter worth approximately $158,000. Eudaimonia Advisors LLC boosted its stake in shares of Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after buying an additional 15,556 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Fennec Pharmaceuticals by 67.7% in the first quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after acquiring an additional 13,223 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.